Further support to the hypothesis of an anti-thrombotic effect of anti-TNF-α agents comes from the abovementioned meta-analysis comparing VTE risk in IBD patients as a complication of systemic CS or anti-TNF-α therapies [21]. Here, TNF is linked to inflammatory bowel disease.